Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

NKTR-255 en association avec la thérapie cellulaire CAR-T pour le traitement du lymphome à grandes cellules B récidivant ou réfractaire

17 septembre 2026 mis à jour par: Fred Hutchinson Cancer Center

Une étude ouverte de phase Ib évaluant l'innocuité et l'efficacité du NKTR-255 en association avec la thérapie cellulaire CAR-T dirigée par CD19 chez des patients atteints de lymphome à grandes cellules B (LBCL) récidivant/réfractaire (R/R)

This phase Ib trial studies the effects of NKTR-255 in combination with chimeric antigen (CAR)-T cell therapy and to see how well they work in treating patients with large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). NKTR-255 is an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. T cells are infection fighting blood cells that can kill tumor cells. Lisocabtagene maraleucel is a CAR-T cell product that consists of genetically engineered T cells, modified to recognize CD19, a protein on the surface of cancer cells. These CD19-specific T cells may help the body's immune system identify and kill CD19-positive cancer cells. Giving NKTR-255 together with lisocabtagene maraleucel may work better in treating large B-cell lymphoma than either drug alone.

Aperçu de l'étude

Description détaillée

OUTLINE:

Patients receive standard of care lymphodepletion therapy consisting of cyclophosphamide and fludarabine on days -5 to -3 followed by liso-cel CAR-T cell infusion on day 0. Patients then receive NKTR-255 intravenously (IV) over 30 minutes every 3 weeks starting on day 10 or 14 in the absence of disease progression or unacceptable toxicity. Patients undergo chest x-ray and echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening. Patients undergo bone marrow biopsy and aspiration, lumbar puncture (LP) for cerebrospinal fluid (CSF) sample collection during screening, on the study and during follow-up as clinically indicated. Patients also undergo positron emission tomography (PET)/computed tomography (CT) throughout the trial. Additionally, patients undergo blood sample collection and may optionally undergo tissue biopsy throughout the trial.

After completion of study treatment, patients are followed up every 30 days then every 3 months up to 12 months after the CAR-T cell infusion.

Type d'étude

Interventionnel

Inscription (Réel)

27

Phase

  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Washington
      • Seattle, Washington, États-Unis, 98109
        • Fred Hutch/University of Washington Cancer Consortium

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Male or female >= 18 years of age at the time of consent
  • Patients with LBCL (including diffuse large B-cell lymphoma [DLBCL] not otherwise specified [including DLBCL arising from indolent lymphoma], high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B) with a Food and Drug Administration (FDA)-approved indication for treatment with liso-cel
  • Fludeoxyglucose F-18 (FDG)-avid disease on positron emission tomography (PET) imaging or pathology evidence of active disease
  • Evidence of CD19 expression on any prior or current tumor specimen or a high likelihood of CD19 expression based on disease histology
  • Karnofsky performance status >= 60%
  • Absolute neutrophil count (ANC) >= 1000 cells/mm^3 in the absence of bone marrow involvement by lymphoma
  • Platelets >= 50,000 cells/mm^3 in the absence of bone marrow involvement by lymphoma
  • Hemoglobin >= 8 g/dL in the absence of bone marrow involvement by lymphoma
  • Calculated creatinine clearance (Cockcroft/Gault) > 30 mL/min/1.73 m^2
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN (or < 5 x ULN for subjects with lymphomatous infiltration of the liver)
  • Total bilirubin =< 2 (or < 3.0 for subjects with Gilbert's syndrome or lymphomatous infiltration of the liver)
  • Common Terminology Criteria for Adverse Events (CTCAE) Grade =< 1 dyspnea
  • Saturation of oxygen (Sa02) >= 92% on room air
  • Patients with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing and must have a forced expiratory volume in 1 second (FEV1) of >= 50% of predicted value
  • Patients with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing and must have a diffusing capacity of the lung for carbon monoxide (DLCO; corrected) >= 40% of predicted value
  • Left ventricular ejection fraction (LVEF) >= 40% as assessed by echocardiogram or multiple uptake gated acquisition (MUGA)
  • Patients with Fridericia's corrected QT interval (QTcF) > 450 ms for men and > 470 ms for women will require clearance by a cardiologist
  • Women of reproductive potential (defined as all women physiologically capable of becoming pregnant) must agree to use suitable methods of contraception for 1 month after the last dose of study therapy (NKTR-255)
  • Males who have partners of reproductive potential must agree to use an effective barrier contraceptive method for 1 month after the last dose of study therapy (NKTR-255)
  • Ability to understand and provide informed consent
  • Able and willing to comply with study visit schedule and procedures, including tumor biopsy where feasible and with acceptable risk

Exclusion Criteria:

  • Planned use of therapeutic doses of corticosteroids (> 20 mg/day prednisone or equivalent) or other systemic immunosuppression within 7 days prior to leukapheresis or within 72 hours prior to liso-cel infusion. Topical and/or inhaled steroids are permitted

  • Prior treatment with any CD19 CAR-T cell therapy

  • For allogeneic hematopoietic cell transplant (HCT) recipients, active graft versus host disease (GVHD) and/or systemic GVHD therapy within 30 days prior to planned leukapheresis

  • Known active hepatitis B (detectable hepatitis B deoxyribonucleic acid [DNA]) or hepatitis C (detectable hepatitis C ribonucleic acid [RNA])

  • Known human immunodeficiency virus (HIV) infection

  • Pregnant or breastfeeding women

  • Prior treatment with any IL-2 or IL-15 agonist and/or biosimilar agents

  • Active autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., ulcerative colitis, Crohn's disease], celiac disease, or other serious chronic gastrointestinal conditions associated with diarrhea, autoimmune vasculitis, systemic lupus erythematosus, Wegener syndrome [granulomatosis with polyangiitis], myasthenia gravis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.) requiring immunosuppressive therapy. The following are exceptions to this criterion:

    • Vitiligo.
    • Alopecia.
    • Hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement.
    • Type 1 diabetes mellitus.
    • Psoriasis not requiring systemic treatment.
    • Conditions considered to be low risk of serious deterioration by the principal investigator (PI).
  • History of any one of the following cardiovascular conditions within the past 6 months: class III or IV heart failure as defined by the New York Heart Association (NYHA), cardiac angioplasty or stenting, myocardial infarction, or unstable angina; unless clearance by a cardiologist is obtained. History of other clinically significant cardiac disease that, in the opinion of the PI or designee, is a contraindication to study treatment is also excluded

  • History or presence of clinically relevant central nervous system (CNS) pathology, such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, or psychosis that in the opinion of the PI is a contraindication to study treatment.

    • Patients with active parenchymal CNS involvement by malignancy will be excluded. Patients with prior or current secondary leptomeningeal CNS disease are eligible. CNS disease prophylaxis must be stopped at least 1 week prior to liso-cel infusion
  • History of solid organ transplantation

  • Active, serious, and uncontrolled infection(s)

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Treatment (lymphodepletion, liso-cel, NKTR-255)

Patients receive standard of care lymphodepletion therapy consisting of cyclophosphamide and fludarabine on days -5 to -3 followed by liso-cel CAR-T cell infusion on day 0. Patients then receive NKTR-255 IV over 30 minutes every 3 weeks starting on day 10 or 14 for up to 3 doses in the absence of disease progression or unacceptable toxicity. Patients undergo chest x-ray and ECHO or MUGA during screening. Patients undergo bone marrow biopsy and aspiration, LP for CSF sample collection during screening, on the study and during follow-up as clinically indicated. Patients also undergo PET/CT throughout the trial. Additionally, patients undergo blood sample collection and may optionally undergo tissue biopsy throughout the trial.

Given IV

Autres noms:
  • Cytoxane
  • CTX
  • (-)-Cyclophosphamide
  • 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroéthyl)amino]tétrahydro-, 2-oxyde, monohydraté
  • Carloxane
  • Ciclofosfamida
  • Ciclofosfamide
  • Cicloxal
  • Clafène
  • Clapène
  • CP monohydraté
  • CYCLO-cellule
  • Cycloblastine
  • Cyclophosphame
  • Cyclophosphamide monohydraté
  • Monohydrate de cyclophosphamide
  • Cyclophosphamide
  • Cyclophosphane
  • Cyclostine
  • Cytophosphane
  • Fosfaséron
  • Genoxal
  • Genuxal
  • Lédoxine
  • Mitoxane
  • Néosar
  • Revimmuniser
  • Syklofosfamide
  • WR-138719
  • Asta B 518
  • B-518

Undergo MUGA

Autres noms:
  • Balayage du bassin sanguin
  • Angiographie à l'équilibre des radionucléides
  • Imagerie du pool sanguin contrôlé
  • MUGA
  • RNVG
  • Numérisation SYMA
  • Numérisation d'acquisition synchronisée à plusieurs portes
  • Numérisation MUGA
  • Balayage d'acquisition multi-portes
  • Balayage du ventriculogramme radionucléide

Undergo x-ray imaging

Autres noms:
  • Radiographie conventionnelle
  • Radiologie diagnostique
  • Imagerie radiographique
  • L'imagerie médicale
  • Radiographies sur film simple

Undergo PET/CT

Autres noms:
  • ANIMAUX
  • Tomographie par émission de positrons
  • imagerie spectroscopique par résonance magnétique du proton
  • PT
  • TEP-scan
  • L'imagerie médicale

Undergo bone marrow biopsy and aspiration

Undergo bone marrow biopsy and aspiration

Autres noms:
  • Biopsie de la moelle osseuse

Given IV

Autres noms:
  • Fluradosa

Undergo ECHO

Autres noms:
  • CE

Undergo PET/CT

Autres noms:
  • TDM
  • Scanner
  • Tomographie axiale informatisée

Given IV

Autres noms:
  • JCAR017
  • Breyanzi
  • Anti-CD19-CAR Lymphocytes T autologues génétiquement modifiés JCAR017
  • Autologue Anti-CD19-EGFRt-4-1BB-zêta modifié CAR lymphocytes T CD8+ et CD4+ JCAR017
  • JCAR 017
  • Liso-cel

Given IV

Autres noms:
  • Agoniste des récepteurs IL-15 NKTR-255
  • IL-15 conjugué à un polymère à action prolongée
  • NKTR 255
  • NKTR-255
  • NKTR255

Undergo LP

Autres noms:
  • LP
  • ponction lombaire

Undergo blood and CSF sample collection

Autres noms:
  • Collecte d'échantillons biologiques

Undergo tissue biopsy

Autres noms:
  • Bx

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Incidence of adverse events (AEs)
Délai: 30 days after the last dose of NKTR-255 or until a new antitumor therapy has been initiated

Grade ≥ 3 AEs considered related to NKTR-255 will be listed and summarized. Summaries of grade ≥ 3 laboratory data will include, at a minimum, treatment-emergent laboratory abnormalities. Summaries of AEs and laboratory abnormalities will be based on the safety evaluable population.

30 days after the last dose of NKTR-255 or until a new antitumor therapy has been initiated
Dose-limiting toxicity (DLT) rates
Délai: Up to 21 days after the first NKTR-255 infusion

Observed DLT rates will be summarized based on the DLT evaluable population. Final DLT rates at each dose level will be estimated by isotonic regression by applying the pooled adjacent violators algorithm.

Up to 21 days after the first NKTR-255 infusion
Optimal biological dose (OBD)
Délai: Up to 12 months after the CAR-T cell infusion

A composite of clinical information will be utilized to determine the OBD based on safety and tolerability, confirmation of maximum target engagement, optimal biological effects without undesirable clinical effects, pharmacokinetic parameters, and biological response data.

Up to 12 months after the CAR-T cell infusion
Complete response (CR) rate
Délai: Up to 3 months after the CAR-T cell infusion

The CR rate will be summarized along with the 2-sided 95% exact Clopper-Pearson confidence interval based on the efficacy evaluable population.

Up to 3 months after the CAR-T cell infusion

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Complete response (CR) and overall response (OR) rates
Délai: Up to 12 months after the CAR-T cell infusion

The CR and OR rates will be summarized along with the 2-sided 95% exact Clopper-Pearson confidence interval based on the efficacy evaluable population.

Up to 12 months after the CAR-T cell infusion
Duration of response (DOR)
Délai: Up to 12 months after the CAR-T cell infusion

Will be assessed among responders. If a patient does not have an event for the DOR analyses, the patient will be censored at the date of the last adequate disease assessments or prior to the earliest censoring event. The censoring reason can include last contact/follow-up, discontinuation or completion of the study, receipt of another anticancer treatment with the exception of consolidation therapy with hematopoietic cell transplantation (HCT), and at least two consecutive missed scheduled disease assessments. Kaplan-Meier (KM) method will be used to analyze DOR.

Up to 12 months after the CAR-T cell infusion
Progression free survival (PFS)
Délai: Up to 12 months after the CAR-T cell infusion

Will be assessed among responders. If a patient does not have an event for the PFS analyses, the patient will be censored at the date of the last adequate disease assessments or prior to the earliest censoring event. The censoring reason can include last contact/follow-up, discontinuation or completion of the study, receipt of another anticancer treatment with the exception of consolidation therapy with HCT, and at least two consecutive missed scheduled disease assessments. KM method will be used to analyze PFS.

Up to 12 months after the CAR-T cell infusion
Overall survival (OS)
Délai: Up to 12 months after the CAR-T cell infusion

Analyses of OS will be performed in the safety population. For assessment of OS, data from surviving patients will be censored at the last time that the patient is known to be alive. KM method will be used to analyze OS.

Up to 12 months after the CAR-T cell infusion

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Collaborateurs

Les enquêteurs

  • Chercheur principal: Alexandre Hirayama, Fred Hutch/University of Washington Cancer Consortium

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

8 décembre 2022

Achèvement primaire (Réel)

4 septembre 2025

Achèvement de l'étude (Réel)

4 septembre 2026

Dates d'inscription aux études

Première soumission

28 avril 2022

Première soumission répondant aux critères de contrôle qualité

28 avril 2022

Première publication (Réel)

3 mai 2022

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

21 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

17 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner